PSE (Pseudoephedrine)

Browse PSE (Pseudoephedrine) Content

CHPA applauds the state of Georgia for becoming the thirty-third state to adopt the real-time, stop-sale technology called the National Precursor Log Exchange (NPLEx).

Apr 28, 2016

CHPA highlights the results of a recent five-state survey from the Asthma and Allergy Foundation of America, which found that consumers on the whole, prefer full access to OTC medicine containing pseudoephedrine.

Jul 22, 2015

So far, 31 states have adopted real-time, stop-sale technology. The blocking technology monitors all nonprescription PSE purchases in real-time to prevent meth criminals from exceeding legal limits.

Mar 31, 2014

Today, the manufacturers of OTC medicines containing pseudoephedrine call on Congress to improve the Combat Methamphetamine Epidemic Act by requiring a unified, national electronic tracking system to block illegal sales of PSE‐containing medicines.

Apr 13, 2010

Letter from the Consumer Healthcare Products Association, the Food Marketing Institute, the Healthcare Distribution Management Association, and the National Association of Chain Drugstores regarding controlled substances and Lis I chemical registration application fees.

Jan 17, 2006

CHPA is deeply concerned that safe and effective medicines manufactured by its member companies are being diverted to manufacture meth. We understand the scope of this problem and are committed to the need for strong action to prevent the diversion of these important medicines to the illegal manufacturing of methamphetamine.

Oct 20, 2005

We submit these comments on behalf of CHPA in response to the proposed rule regarding security requirements for manufacturers, distributors, importers, and exporters of pseudoephedrine, ephedrine, and phenylpropanolamine.

Oct 28, 2004

This letter is submitted on behalf of CHPA, FMI, HDMA, and NACDS. The purpose of the letter is to express our united concern that the DEA’s proposed rule is not supported by existing evidence and will impose a significant burden on the regulated industry.

Oct 22, 2004

CHPA and its members share DEA's concerns regarding the diversion of pseudoephedrine, ephedrine, and phenylpropanolamine products. However, CHPA does not believe that the notice of proposed rulemaking provides interested parties an adequate record to evaluate and comment upon the security measures DEA now proposes.

Sep 20, 2004

These comments are in response to the "interpretive rule" DEA published to provide a "Clarification of the Exemption of Sales by Retail Distributors of Pseudoephedrine and Phenylpropanolamine Products."

Feb 27, 2004

Filter Results